Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mycobacteroides abscessus

ABSTRACT: Development of a novel DNA chromatography discriminating of Mycobacterium abscessus subspecies and macrolide susceptibility.

PROVIDER: PRJDB10333 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	DRR245150_1.fastq.gz	Fastqsanger.gz
	DRR245150_2.fastq.gz	Fastqsanger.gz
	DRR245151_1.fastq.gz	Fastqsanger.gz
	DRR245151_2.fastq.gz	Fastqsanger.gz
	DRR245152_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 296

Similar Datasets

Overlap in antibiotic stress responses leads to cross-resistance between ribosomal acting drugs in Mycobacterium abscessus.

Project description:Mycobacterium abscessus is an opportunistic pathogen notorious for its resistance to most classes of antibiotics and low cure rates. In addition to the highly impermeable mycomembrane, M. abscessus carries an array of shared and species-specific defence mechanisms. However, it remains unknown whether M. abscessus’ antibiotic stress response is fine-tuned or an all-or-nothing response. A deeper understanding of underlying resistance and tolerance mechanisms is pivotal in development of targeted therapeutic regimens. We elucidate the transcriptomic response of M. abscessus to antibiotics recommended in treatment guidelines. The M. abscessus ATCC 19977 strain was used. Bacteria were subjected to sub-inhibitory concentrations of drugs for 4- and 24-hours, followed by RNA sequencing. In addition, time-kill kinetic analysis was performed using bacteria after pre-exposure to clarithromycin, amikacin or tigecycline for 24-hours. Lastly, Pan-genome analysis of 35 strains from all three subspecies was performed. Mycobacterium abscessus shows both drug-specific and communal transcriptomic responses to antibiotic exposure. Key features of its tolerance to antibiotics are drug-specific converting enzymes, target protection and shifts in its respiratory chain and metabolic state. The observed transcriptomic responses are likely not strain-specific, as genes involved in tolerance are found in all included strains, with the exception of erm(41) in M. abscessus subspecies massiliense. Due to the communal response elicited by ribosomal-targeting antibiotics, exposure to any of these drugs rapidly induces tolerance mechanisms that decrease susceptibility to ribosome-targeting drugs from multiple classes. Screening high-risk patients (e.g. those with bronchiectasis) for M. abscessus infection prior to starting macrolide or aminoglycoside maintenance therapy is warranted.

2022-01-25 | GSE163621 | GEO

Cyclophostin and Cyclipostins analogues counteract macrolide-induced resistance mediated by Erm(41) in Mycobacterium abscessus

Project description:Mycobacterium abscessus is an emerging pathogen causing severe pulmonary infections, particularly in individuals with underlying conditions, such as cystic fibrosis or chronic obstructive pulmonary disease. Macrolides, including clarithromycin (CLR) and azithromycin (AZM), represent the current cornerstone of antibiotherapy against M. abscessus complex. However, prolonged exposure to macrolides can induce the apparition of Erm(41)-mediated resistance, limiting their spectrum of activity and often leading to therapeutic failure. Therefore, inhibiting Erm(41) could thwart this resistance mechanism to maintain macrolide susceptibility and avoid the therapeutic failure. In a previous study, the Erm(41) methyltransferase was identified as a target enzyme of Cyclipostins and Cyclophostin compounds (CyC). Herein, we took advantage of this feature to evaluate the in vitro activity of clarithromycin and azithromycin in combination with different CyC via the checkerboard assay on macrolide susceptible and induced macrolide-resistant M. abscessus generated by either clarithromycin or azithromycin exposure. Our results emphasize the use of the CyC to prevent/overcome Erm(41) induced resistance, restore macrolide susceptibility. This work should help to expand our therapeutic arsenal in the fight against a particularly antibiotic resistant mycobacterial species and could provide the opportunity to revisit the therapeutic regimen for combating M. abscessus pulmonary infections in CF patients, and particularly in erm(41)-positive strains.

2024-12-05 | PXD055560 | Pride

Mycobacteroides abscessus subsp. abscessus

Project description:Mycobacterium abscessus subsp. abscessus re-sequencing

| PRJNA734909 | ENA

Mycobacteroides abscessus

Project description:Genome sequence and assembly of 123 Mycobacterium abscessus subsp. abscessus isolates and 39 Mycobacterium abscessus subsp. massiliense isolates

| PRJNA398137 | ENA

Human pluripotent stem cell-derived macrophages host Mycobacterium abscessus infection

Project description:Generation and analysis of human macrophages from induced pluripotent stem cells were infected by Mycobacterium abscessus to examine susceptibility and transcriptomic response

2022-08-10 | GSE183865 | GEO

Mycobacteroides abscessus M172

Project description:Mycobacterium abscessus M172 Genome sequencing

| PRJNA89599 | ENA

Mycobacteroides abscessus M115

Project description:Mycobacterium abscessus M115 Genome sequencing

| PRJNA89601 | ENA

Mycobacteroides abscessus M154

Project description:Mycobacterium abscessus M154 Genome sequencing

| PRJNA89603 | ENA

Mycobacteroides abscessus M94

Project description:Mycobacterium abscessus M94 Genome sequencing